Breast Neoplasms
Carcinoma, Non-Small-Cell Lung
Docetaxel
Prostatic Neoplasms
Stomach Neoplasms

Docetaxel

Docetaxel, in combination with cisplatin, is approved by the Federal Drug Agency (FDA) as a first-line treatment for prostate cancer and is the standard of care for castration-resistant prostate cancer. The medication is effective in non small cell lung cancer (NSCLC), particularly for patients with poor prognosis or metastatic disease, and is a standard adjunct in breast cancer treatment. Additionally, docetaxel is part of the TEX regimen for advanced gastric cancer and can be considered for stage IV NSCLC after previous therapies. This activity focuses on the indications, mechanism of action, and administration of docetaxel. Participating clinicians are equipped to identify adverse drug reactions, clinical monitoring, pharmacokinetics, drug interactions, toxicity, contraindications, and FDA-issued box warnings. An interprofessional team, including oncologists, pharmacists, and nursing staff, is crucial for optimizing cancer treatment outcomes with docetaxel. Effective patient-centered care requires coordination, communication, and collaboration to manage adverse events, monitor progress, and provide comprehensive patient education.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.